logo

For the Inventor, By the Inventor

Montreal, Canada

Methylgene, Inc.

USPTO Granted Patents = 53

% Expired Patents = 41.5



Forward Citations = 538

Loading Chart...
Loading Chart...

76 inventors (with patents filed for the assignee):

goldMedal Arkadii Vaisburg (28 out of 33 patents)

silverMedal Stephen Claridge (14 out of 20 patents)

bronzeMedal Lijie Zhan (14 out of 14 patents)

4.  Daniel Delorme (13 out of 38 patents)

5.  Ljubomir Isakovic (12 out of 12 patents)

6.  Michael Mannion (12 out of 12 patents)

7.  Stephane Raeppel (12 out of 14 patents)

8.  Jeffrey M Besterman (11 out of 12 patents)

9.  Silvana Leit (10 out of 11 patents)

10.  Oscar Mario Saavedra (10 out of 10 patents)

11.  Sylvie Frechette (10 out of 10 patents)

12.  Franck Raeppel (9 out of 13 patents)

13.  Jubrail Rahil (9 out of 10 patents)

14.  Oscar Miguel Moradei (8 out of 32 patents)

15.  Frederic Gaudette (8 out of 8 patents)


Core Competencies:
HDAC Inhibitors
Protein Tyrosine Kinase
DNA Methyltransferase
Fused Heterocycles
Beta-Lactamase
Gene Expression
Antifungal Agents
Combination Therapy
VEGF Receptor
HGF Receptor
Antisense Oligonucleotides
Histone Deacetylase

53 patents:

1. 9193749 - Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors (2015-11-24),
2. 9096565 - Inhibitors of histone deacetylase (2015-08-04),
3. 9018378 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2015-04-28),
4. 8907091 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2014-12-09),
5. 8906852 - Inhibitors of protein tyrosine kinase activity (2014-12-09),
6. 8846927 - Inhibitors of protein tyrosine kinase activity (2014-09-30),
7. 8796330 - Inhibitors of histone deacetylase and prodrugs thereof (2014-08-05),
8. 8759522 - Inhibitors of protein tyrosine kinase activity (2014-06-24),
9. 8759400 - Histone deacetylase inhibitors for enhancing activity of antifungal agents (2014-06-24),
10. 8729268 - Inhibitors of protein tyrosine kinase activity (2014-05-20),
11. 8673911 - Inhibitors of histone deacetylase (2014-03-18),
12. 8598168 - Inhibitors of histone deacetylase (2013-12-03),
13. 8569503 - Processes and intermediates for preparing fused heterocyclic kinase inhibitors (2013-10-29),
14. 8470850 - Inhibitors of VEGF receptor and HGF receptor signalling (2013-06-25),
15. 8455484 - Selected inhibitors of protein tyrosine kinase activity (2013-06-04),
Company Overview
Methylgene, Inc. is a biotechnology company based in Montreal, Canada, specializing in drug discovery with a focus on innovative therapeutic solutions. The company is engaged in the development of small molecule inhibitors targeting critical pathways in cancer and other diseases, particularly through the use of HDAC inhibitors and protein tyrosine kinase modulators. Methylgene's research encompasses various core technology areas, including DNA methyltransferase, antifungal agents, and combination therapies, aiming to advance treatment options and improve patient outcomes.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

53 Patents

#18 in Montreal

#258 in Canada

#13,348 in the World

Montreal, CA
Montreal, Canada

Methylgene, Inc.

Forward Citations = 538

76 inventors:

goldMedal Arkadii Vaisburg (28 out of 33 patents)

silverMedal Stephen Claridge (14 out of 20 patents)

bronzeMedal Lijie Zhan (14 out of 14 patents)

4.  Daniel Delorme (13 out of 38 patents)

5.  Ljubomir Isakovic (12 out of 12 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Methylgene, Inc.. Retrieved from https://idiyas.com/company/methylgene

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…